The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Current understanding of Alzheimer’s disease diagnosis and treatment
Open accessAbstract
Alzheimer’s disease is the most common cause of dementia worldwide, with the prevalence continuing to grow in part because of the aging world population. This neurodegenerative disease process is characterized classically by two hallmark pathologies: β-amyloid plaque deposition and neurofibrillary tangles of hyperphosphorylated tau. Diagnosis is based upon clinical presentation fulfilling several criteria as well as fluid and imaging biomarkers. Treatment is currently targeted toward symptomatic therapy, although trials are underway that aim to reduce the production and overall burden of pathology within the brain. Here, we discuss recent advances in our understanding of the clinical evaluation and treatment of Alzheimer’s disease, with updates regarding clinical trials still in progress.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, both PET imaging and CSF analysis exhibit similar accuracy, and suggest that the optimum test for the diagnosis will depend upon patient/provider preference, cost and availability of facilities [37].”
From Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease (2020) · cites this paper as [37]
In the citing paper
“Current therapeutics to ameliorate and control the cognitive and behavioral symptoms by targeting the NMDA receptor prevent Ca2+ induced excitotoxicity [2, 9–11], and memantine was approved for this purpose in 2003.”
From Current therapeutics for Alzheimer’s disease and clinical trials (2024) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
Diagnostic and Statistical Manual of Mental Disorders
Siegel, L. J., & Fletcher‐Janzen, E. (2008) · Wiley eBooks · doi:10.1002/9780470373699.speced0655 · Cited by 8,467
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Mechanisms of Gamma Oscillations
Buzsáki, G., & Wang, X.-J. (2012) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-062111-150444 · Cited by 2,796
Albert, M., DeKosky, S. T., Dickson, D. W., Dubois, B., Feldman, H., Fox, N. C., Gamst, A. C., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2013) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.11.1.96 · Cited by 2,643
Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
2017 Alzheimer's disease facts and figures
(, T. D. B. T. A.-R. C. C. A. S. O. A. C. B. S., different, ). J. A. I. A., destroyed, S. A. T. A. S. T. M. E. T. M. C. I. S. I. A. G. W. A. T. R. N. I. T. O. B. T. F. N. T. B. D. A. D. A. U. I. B. R. I. I. F. N. M. A. N. I. O. P. O. T. B. A. D. A., difficulties, I. E. O., agitation, I. N. S. S. A., & delusions., S. A. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.02.001 · Cited by 1,366
Gamma frequency entrainment attenuates amyloid load and modifies microglia
Iaccarino, H. F., Singer, A. C., Martorell, A. J., Rudenko, A., Gao, F., Gillingham, T. Z., Mathys, H., Seo, J., Kritskiy, O., Abdurrob, F., et al. (2016) · Nature · doi:10.1038/nature20587 · Cited by 1,328
Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705971 · Cited by 1,049
Clark, C. M., Pontecorvo, M. J., Beach, T. G., Bedell, B. J., Coleman, R. E., Doraiswamy, P. M., Fleisher, A. S., Reiman, E. M., Sabbagh, M. N., Sadowsky, C. H., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70142-4 · Cited by 855
Donepezil and memantine for moderate-to-severe Alzheimer's disease
Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A., Dening, T., Findlay, D., Holmes, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106668 · Cited by 782
Alzheimer’s disease prevention: from risk factors to early intervention
Crous‐Bou, M., Minguillón, C., Gramunt, N., & Molinuevo, J. L. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0297-z · Cited by 730
Singh, B., Parsaik, A. K., Mielke, M. M., Erwin, P. J., Knopman, D. S., Petersen, R. C., & Roberts, R. O. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-130830 · Cited by 700
Vitamin D and the risk of dementia and Alzheimer disease
Littlejohns, T. J., Henley, W., Lang, I., Annweiler, C., Beauchet, O., Chaves, P. H. M., Fried, L. F., Kestenbaum, B. R., Kuller, L. H., Langa, K. M., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000755 · Cited by 595
The road to restoring neural circuits for the treatment of Alzheimer's disease
Canter, R. G., Penney, J., & Tsai, L.-H. (2016) · Nature · doi:10.1038/nature20412 · Cited by 565
Core candidate neurochemical and imaging biomarkers of Alzheimer's disease
Hampel, H. J., Bürger, K., Teipel, S. J., Bokde, A. L. W., Zetterberg, H., & Blennow, K. (2007) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2007.08.006 · Cited by 552
Mediterranean Diet, Cognitive Function, and Dementia: A Systematic Review
Lourida, I., Soni, M., Thompson-Coon, J., Purandare, N., Lang, I. A., Ukoumunne, O. C., & Llewellyn, D. J. (2013) · Epidemiology · doi:10.1097/ede.0b013e3182944410 · Cited by 521
Kennedy, M. E., Stamford, A. W., Chen, X., Cox, K., Cumming, J. N., Dockendorf, M. F., Egan, M. F., Ereshefsky, L., Hodgson, R. A., Hyde, L. A., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad9704 · Cited by 441
BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease
Vassar, R. J. (2014) · Alzheimer s Research & Therapy · doi:10.1186/s13195-014-0089-7 · Cited by 421
Gorelick, P. B., Furie, K. L., Iadecola, C., Smith, E. E., Waddy, S. P., Lloyd-Jones, D. M., Bae, H.-J., Bauman, M. A., Dichgans, M., Duncan, P. W., et al. (2017) · Stroke · doi:10.1161/str.0000000000000148 · Cited by 411
Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease
Palmqvist, S., Zetterberg, H., Mattsson, N., Johansson, P., Initiative, F. T. A. D. N., Minthon, L., Blennow, K., Olsson, M., For the Swedish BioFINDER study group, Hansson, O., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001991 · Cited by 375
Novák, P., Schmidt, R., Kontseková, E., Žilka, N., Kováčech, B., Škrabana, R., Kazmerova, Z., Katina, S., Fialová, Ľ., Prčina, M., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30331-3 · Cited by 306
Takizawa, C., Thompson, P. L., van Walsem, A., Faure, C., & Maier, W. C. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-141134 · Cited by 261
Tau immunotherapy for Alzheimer's disease
Pedersen, J. T., & Sigurdsson, E. M. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.03.003 · Cited by 247
Lee, L. K., Shahar, S., Chin, A.-V., & Yusoff, N. A. M. (2013) · Psychopharmacology · doi:10.1007/s00213-012-2848-0 · Cited by 219
Serum MicroRNA Profiles Serve as Novel Biomarkers for the Diagnosis of Alzheimer’s Disease
Dong, H., Li, J., Huang, L., Chen, X., Li, D., Wang, T., Hu, C., Xu, J. L., Zhang, C., Zen, K., et al. (2015) · Disease Markers · doi:10.1155/2015/625659 · Cited by 217
Beta-amyloid imaging with florbetaben
Sabri, O., Seibyl, J. P., Rowe, C. C., & Barthel, H. (2015) · Clinical and Translational Imaging · doi:10.1007/s40336-015-0102-6 · Cited by 177
Physical activity reduces hippocampal atrophy in elders at genetic risk for Alzheimer's disease
Smith, J. C., Nielson, K. A., Woodard, J. L., Seidenberg, M., Durgerian, S., Hazlett, K. E., Figueroa, C. M., Kandah, C. C., Kay, C. D., Matthews, M. A., et al. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00061 · Cited by 172
Grossberg, G. T., Manes, F. F., Allegri, R., Gutiérrez‐Robledo, L. M., Gloger, S., Xie, L., Jia, X., Pejović, V., Miller, M. L., Perhach, J. L., et al. (2013) · CNS Drugs · doi:10.1007/s40263-013-0077-7 · Cited by 163
Gamma Oscillations Distinguish True From False Memories
Sederberg, P. B., Schulze‐Bonhage, A., Madsen, J. R., Bromfield, E. B., Litt, B., Brandt, A., & Kahana, M. J. (2007) · Psychological Science · doi:10.1111/j.1467-9280.2007.02003.x · Cited by 153
Bo, Y., Zhang, X., Wang, Y., You, J., Cui, H., Zhu, Y., Pang, W., Liu, W. Y., Jiang, Y., & Lü, Q. (2017) · Nutrients · doi:10.3390/nu9010054 · Cited by 137
Propagation of tau pathology in Alzheimer’s disease: identification of novel therapeutic targets
Pooler, A. M., Polydoro, M., Wegmann, S., Nicholls, S. B., Spires‐Jones, T. L., & Hyman, B. T. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt214 · Cited by 130
Shen, Y., Wang, H., Sun, Q., Yao, H., Keegan, A. P., Mullan, M., Wilson, J., Lista, S., Leyhe, T., Laske, C., et al. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.02.007 · Cited by 123
Huperzine A in the Treatment of Alzheimer′s Disease and Vascular Dementia: A Meta‐Analysis
Xing, S.-H., Zhu, C., Zhang, R., & An, L. (2014) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2014/363985 · Cited by 117
Tau-Based Therapeutics for Alzheimer’s Disease: Active and Passive Immunotherapy
Panza, F., Solfrizzi, V., Seripa, D., Imbimbo, B. P., Lozupone, M., Santamato, A., Tortelli, R., Galizia, I., Prete, C., Daniele, A., et al. (2016) · Immunotherapy · doi:10.2217/imt-2016-0019 · Cited by 113
Jacobsen, H., Ozmen, L., Caruso, A., Narquizian, R., Hilpert, H., Jacobsen, B., Terwel, D., Tanghe, A., & Bohrmann, B. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.1405-14.2014 · Cited by 96
A systematic review and meta‐analysis of 18F‐labeled amyloid imaging in Alzheimer's disease
Yeo, J. M., Waddell, B., Khan, Z. H., & Pal, S. (2015) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2014.11.004 · Cited by 83
Dregan, A., & Gulliford, M. C. (2013) · Psychological Medicine · doi:10.1017/s0033291713000305 · Cited by 72
Stella, F., Canonici, A. P., Gobbi, S., Galduróz, J. C. F., Cação, J. D. C., & Gobbi, L. T. B. (2011) · Clinics · doi:10.1590/s1807-59322011000800008 · Cited by 65
New Criteria for Alzheimer Disease and Mild Cognitive Impairment
Budson, A. E., & Solomon, P. R. (2012) · The Neurologist · doi:10.1097/nrl.0b013e31826a998d · Cited by 65
Self-citationBuilding a roadmap for developing combination therapies for Alzheimer’s disease
Perry, D. P., Sperling, R. A., Katz, R. G., Berry, D. A., Dilts, D. M., Hanna, D. L., Salloway, S., Trojanowski, J. Q., Bountra, C., Krams, M., et al. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.996551 · Cited by 53
Cortical florbetapir-PET amyloid load in prodromal Alzheimer’s disease patients
Saint‐Aubert, L., Barbeau, E. J., Péran, P., Nemmi, F., Vervueren, C., Mirabel, H., Payoux, P., Hitzel, A., Bonneville, F., Gramada, R., et al. (2013) · EJNMMI Research · doi:10.1186/2191-219x-3-43 · Cited by 53
Immunotherapy for Targeting Tau Pathology in Alzheimer’s Disease and Tauopathies
Rosenmann, H. (2013) · Current Alzheimer Research · doi:10.2174/1567205011310030001 · Cited by 52
Management of patients with Alzheimer’s disease: pharmacological treatment and quality of life
Mossello, E., & Ballini, E. (2012) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622312452387 · Cited by 51
Role of Traditional Nonsteroidal Anti-inflammatory Drugs in Alzheimer’s Disease
Gupta, P. P., Pandey, R. D., Jha, D., Shrivastav, V. K., & Kumar, S. (2014) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317514542644 · Cited by 46
EU/US/CTAD TASK FORCE: LESSONS LEARNED FROM RECENT AND CURRENT ALZHEIMER’S PREVENTION TRIALS
Aisen, P. S. S., Touchon, J., Amariglio, R. E., Andrieu, S., Bateman, R. J., Breitner, J. C. S., Donohue, M. A., Dunn, B., Doody, R. S., Fox, N. C., et al. (2017) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2017.13 · Cited by 43
Amyloid or tau: the chicken or the egg?
Mann, D. M. A., & Hardy, J. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1162-1 · Cited by 39
Reply: the early pathological process in sporadic Alzheimer’s disease
Braak, H., & Tredici, K. D. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1170-1 · Cited by 36
Diseases: Study neuron networks to tackle Alzheimer's
Kosik, K. S. (2013) · Nature · doi:10.1038/503031a · Cited by 15
Cited by
Sorted by citations
Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease
Khan, S., Barve, K. H., & Kumar, M. S. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200528142429 · Cited by 820
“However, both PET imaging and CSF analysis exhibit similar accuracy, and suggest that the optimum test for the diagnosis will depend upon patient/provider preference, cost and availability of facilities [37].”
BackgroundMolecular mechanisms of ferroptosis and their involvement in brain diseases
Costa, I., Barbosa, D. J., Benfeito, S., Silva, V., Chavarria, D., Borges, F., Remião, F., & Silva, R. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108373 · Cited by 402
The role of astroglia in Alzheimer's disease: pathophysiology and clinical implications
Arranz, A. M., & De Strooper, B. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30490-3 · Cited by 334
Monteiro, A. R., Barbosa, D. J., Remião, F., & Silva, R. V. D. S. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115522 · Cited by 375
The Microbiota–Gut–Brain Axis and Alzheimer’s Disease: Neuroinflammation Is to Blame?
Megur, A., Baltriukienė, D., Bukelskienė, V., & Burokas, A. (2020) · Nutrients · doi:10.3390/nu13010037 · Cited by 323
Metadata
- Authors
- Weller, J., & Budson, A.
- Affiliations
- Boston University (US)
- Corresponding author
- Weller, Jason
- Venue
- F1000Research
- Publisher
- F1000 Research Ltd
- Published
- 2018-07-31
- Volume
- 7
- Pages
- 1161
- ISSN
- 2046-1402 (ISSN-L)
- PMC
- PMC6073093
- OpenAlex
- W2885706121
- Cited by
- 1,083
- References
- 53
- Citations by year
- 2026: 67 · 2025: 155 · 2024: 147 · 2023: 176 · 2022: 221 · 2021: 194 · 2020: 92 · 2019: 29 · 2018: 2
- FWCI
- 12.28
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- F1000Research (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Institute on Aging (P30AG013846)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- Alzheimer's disease, dementia, amyloid plaques, tau hyperphosphorylation, neurofibrillary tangles, biomarkers, diagnosis, symptomatic treatment, disease-modifying therapy, clinical trials, neurodegeneration
- MeSH terms
- Alzheimer Disease, Humans, Nerve Net, Amyloid beta-Peptides, tau Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
